Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 140

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 140
---
 SKNY will
merge into the Company through a stock exchange, with each outstanding share of SKNY’s common stock being exchanged for shares of
MIRA’s common stock. The exact exchange ratio will be determined by an independent third-party valuation firm (the “Independent
Valuator”) based on the relative values of both companies. The completion of the Acquisition is contingent upon the Independent
Valuator determining that SKNY’s valuation is at least equal to or greater than that of the Company.

Both parties have agreed to a 90-day mutual due diligence period, during
which they will work in good faith to negotiate and execute a definitive stock purchase agreement and any related transaction documents.
Upon completion of the Acquisition, all of SKNY’s assets, including its drug candidates, will become wholly owned by MIRA, further
expanding the Company’s development pipeline

ATM
Offering

From
January 1, 2025 through March 28, 2025, under the ATM Agreement, the Company sold and issued 2,802 shares of Common Stock at
an average price per share of $1.33, and received net proceeds of approximately $0.003 million, after deducting commissions and
other fees of $0.0003 million.

F-21

SIGNATURES

In
accordance with Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

    MIRA
    PHARMACEUTICALS, INC.

    Date:
    March 28, 2025
    By:
    /S/
    Erez Aminov

    Name:
    Erez
    Aminov

    Title:
    
    Chief
    Executive Officer

    (Principal
    Executive Officer)

    By:
    /S/
    Michelle Yanez

    Name:
    Michelle
    Yanez

    Title:
    Chief
    Financial Officer

    (Principal
    Financial Officer)

In
accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated.

    Person
     
    Capacity
     
    Date

    /s/
    Erez Aminov
     
    Chief
    Executive Officer and Chairman
     
    March
    28, 2025
  
    Erez